Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
6.88
-0.16 (-2.27%)
At close: Aug 12, 2022 4:00 PM
6.65
-0.23 (-3.34%)
After-hours:
Aug 12, 2022 7:59 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Year | 2020 | 2019 |
|---|---|---|
| Revenue
|
0.12 | 0.1 |
| Revenue Growth (YoY)
|
23.97% | - |
| Cost of Revenue
|
0.13 | 0.05 |
| Gross Profit
|
-0.01 | 0.05 |
| Selling, General & Admin
|
0.51 | 0.61 |
| Research & Development
|
0.12 | 0.09 |
| Operating Expenses
|
0.64 | 0.7 |
| Operating Income
|
-0.64 | -0.65 |
| Interest Expense / Income
|
0.03 | 0.09 |
| Other Expense / Income
|
-0.02 | -0.03 |
| Pretax Income
|
-0.65 | -0.71 |
| Net Income
|
-0.65 | -0.71 |
| Net Income Common
|
-0.65 | -0.71 |
| Shares Outstanding (Basic)
|
2 | 1 |
| Shares Outstanding (Diluted)
|
2 | 1 |
| Shares Change
|
130.43% | - |
| EPS (Basic)
|
-0.41 | -1.14 |
| EPS (Diluted)
|
-0.41 | -1.14 |
| Free Cash Flow Per Share
|
-0.24 | -0.71 |
| Gross Margin
|
-7.60% | 45.80% |
| Operating Margin
|
-520.50% | -652.10% |
| Profit Margin
|
-525.80% | -711.30% |
| Free Cash Flow Margin
|
-476.60% | -745.50% |
| EBITDA
|
-0.62 | -0.62 |
| EBITDA Margin
|
-502.60% | -620.50% |
| EBIT
|
-0.62 | -0.62 |
| EBIT Margin
|
-502.60% | -620.50% |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).